TherapeuticsMD, Inc.
TXMD evidence brief
What we can confirm
- BioSniper Score:
- 7.7 / 10
- Market Cap:
- $23.6M
- Next Catalyst:
- Patent_Expiry · Nov 21, 2032
What it means
What to watch
Prepared research question
What matters most for TXMD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TXMD
TherapeuticsMD is a pharmaceutical royalty company that, after exiting its original women's healthcare business in 2022, now generates revenue from royalties on licensed products including IMVEXXY, BIJUVA, and ANNOVERA, with a small revenue base and a single-employee structure as of 2025.
Key risk: Going concern risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 3 catalysts for TherapeuticsMD, Inc..
TherapeuticsMD is a pharmaceutical royalty company that, after exiting its original women's healthcare business in 2022, now generates revenue from royalties on licensed products including IMVEXXY, BIJUVA, and ANNOVERA, with a small revenue base and a single-employee structure as of 2025.
- TherapeuticsMD changed its business model in December 2022 to become a pharmaceutical royalty company, licensing its products to partners like Mayne Pharma, Theramex, and Knight [sec_mda · as of 2026-08-11].
- As of June 30, 2026, the company held cash and cash equivalents of $9,189 thousand [sec_mda · as of 2026-08-11].
- Latest reported financials (as of 2026-06-30) show total revenue of $0.9M, net income of $0.2M, and shareholders' equity of $27.1M [sec].
- The company's approved pipeline products include IMVEXXY (estradiol vaginal inserts), BIJUVA (estradiol/progesterone capsules), and ANNOVERA (ethinyl estradiol/segesterone acetate vaginal ring), all licensed to partners [pipeline].
- As of December 31, 2025, TherapeuticsMD employed only one full-time employee [sec_mda · as of 2026-03-30].
What works
- The company has transitioned to a low-overhead royalty model, with only one employee as of December 31, 2025, which reduces operational costs [sec_mda · as of 2026-03-30].
- It holds approved products (IMVEXXY, BIJUVA, ANNOVERA) with exclusive license agreements in the U.S. and multiple international territories, providing a diversified royalty stream [pipeline] [sec_mda · as of 2026-08-11].
- The company has positive shareholders' equity of $27.1M as of 2026-06-30, indicating a net asset position [sec].
What to weigh
- The company's revenue is very small ($0.9M as of 2026-06-30), reflecting its reliance on royalty income from partners rather than direct product sales [sec].
- There is a going concern risk: the company's financial statements note 'doubt about our ability to continue as a going concern for the next twelve months' as of August 2026 [sec_mda · as of 2026-08-11].
- The company has a very thin operational structure (one employee), which may limit its ability to manage or enforce its license agreements effectively [sec_mda · as of 2026-03-30].
- Cash and cash equivalents of $9,189 thousand as of June 30, 2026, are modest and may not sustain operations if royalty income declines [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
The company changed its business to a royalty model in December 2022.
“In December 2022, we changed our business to become a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories.”
SEC MD&A · August 11, 2026
Cash position as of June 30, 2026.
“As of June 30, 2026, we had cash and cash equivalents totaling $9,189 thousand.”
SEC MD&A · August 11, 2026
Going concern doubt.
“doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements.”
SEC MD&A · August 11, 2026
Employee count as of December 31, 2025.
“As of December 31, 2025, we employed one full-time employee primarily engaged”
SEC MD&A · March 30, 2026
Catalyst timeline
- 2032-11-21 · Patent_Expiry · ESTRADIOL; PROGESTERONE (BIJUVA) — Patent expiry for NDA210132 (BIJUVA) could open the market to generic competition, potentially reducing royalty income.
- 2034-02-02 · Patent_Expiry · ESTRADIOL (IMVEXXY) — Patent expiry for NDA208564 (IMVEXXY) may allow generic entrants, impacting royalties.
- 2039-06-21 · Patent_Expiry · ETHINYL ESTRADIOL; SEGESTERONE ACETATE (ANNOVERA) — Patent expiry for NDA209627 (ANNOVERA) could lead to generic competition, affecting long-term royalty streams.
Risks & what to watch (4)›
Key risks
- Going concern risk — The company's financial statements express doubt about its ability to continue as a going concern for the next twelve months [sec_mda · as of 2026-08-11].
- Low revenue base — Total revenue is only $0.9M as of 2026-06-30, indicating limited royalty income [sec].
- Single-employee structure — With only one employee as of December 31, 2025, the company has minimal operational capacity [sec_mda · as of 2026-03-30].
- Modest cash reserves — Cash and cash equivalents of $9,189 thousand as of June 30, 2026, may not cover extended operational needs [sec_mda · as of 2026-08-11].
What to watch
- Monitor royalty revenue trends from Mayne Pharma, Theramex, and Knight licensees, as they are the sole source of income [sec_mda · as of 2026-08-11].
- Watch for any changes in the company's going concern status or potential restructuring, given the explicit doubt in financial statements [sec_mda · as of 2026-08-11].
- Track patent expirations for key products (e.g., BIJUVA patent expiry in 2032, ANNOVERA in 2039) which could affect competitive positioning [catalyst_timeline].
- Observe any new license agreements or expansions into additional territories that could boost royalty income [sec_mda · as of 2026-08-11].
Sources: Pipeline · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run TherapeuticsMD, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available TherapeuticsMD, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.38 · 1% dilution
No tracked pipeline phase
No tracked pipeline candidates
3 upcoming, next in ~2229d
No insider transactions in the last 180 days
Catalysts
Financials
Short Interest
as of May 22, 2026- % of float
- 0.7%
- Days to cover
- 2.4
- Shares short
- 56,765
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TXMD short interestGovernance
Frequently asked questions
What is the AI investment thesis for TherapeuticsMD, Inc.?
TherapeuticsMD is a pharmaceutical royalty company that, after exiting its original women's healthcare business in 2022, now generates revenue from royalties on licensed products including IMVEXXY, BIJUVA, and ANNOVERA, with a small revenue base and a single-employee structure as of 2025.
What is TherapeuticsMD, Inc.'s next catalyst?
TherapeuticsMD, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA210132" — expected November 21, 2032.
Who is the CEO of TherapeuticsMD, Inc.?
Mr. Marlan D. Walker J.D. is the chief executive officer of TherapeuticsMD, Inc. (TXMD).
Where is TherapeuticsMD, Inc. headquartered?
TherapeuticsMD, Inc. (TXMD) is headquartered in Boca Raton, FL, United States.
What therapeutic areas does TherapeuticsMD, Inc. focus on?
TherapeuticsMD, Inc. develops therapies across Pain, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.